346 related articles for article (PubMed ID: 25204372)
1. Impact of pre-transplant disease burden on the outcome of allogeneic hematopoietic stem cell transplant in refractory and relapsed acute myeloid leukemia: a single-center study.
Tian H; Chen GH; Xu Y; Ma X; Chen F; Yang Z; Jin ZM; Qiu HY; Sun AN; Wu DP
Leuk Lymphoma; 2015 May; 56(5):1353-61. PubMed ID: 25204372
[TBL] [Abstract][Full Text] [Related]
2. [Impact of disease status on outcomes of allogeneic hematopoietic stem cell transplantation in patients with refractory and relapsed acute myeloid leukemia].
Zhou QL; Tang XW; Sun AN; Qiu HY; Jin ZM; Miao M; Fu ZZ; Zhao BR; Shi XL; Chen GH; Wu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):954-8. PubMed ID: 22931663
[TBL] [Abstract][Full Text] [Related]
3. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis.
Chang YJ; Wang Y; Liu YR; Xu LP; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Huang XJ
J Hematol Oncol; 2017 Jul; 10(1):134. PubMed ID: 28676064
[TBL] [Abstract][Full Text] [Related]
4. Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation.
Zhao X; Wang Z; Ruan G; Liu Y; Wang Y; Zhang X; Xu L; Huang X; Chang Y
Ann Hematol; 2018 Jun; 97(6):967-975. PubMed ID: 29423758
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic stem cell transplant overcomes poor prognosis of acute myeloid leukemia with myelodysplasia-related changes.
Ikegawa S; Doki N; Kurosawa S; Yamaguchi T; Sakaguchi M; Harada K; Yamamoto K; Hino Y; Shingai N; Senoo Y; Watanabe K; Igarashi A; Najima Y; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K
Leuk Lymphoma; 2016; 57(1):76-80. PubMed ID: 26084204
[TBL] [Abstract][Full Text] [Related]
6. Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.
Kayser S; Benner A; Thiede C; Martens U; Huber J; Stadtherr P; Janssen JW; Röllig C; Uppenkamp MJ; Bochtler T; Hegenbart U; Ehninger G; Ho AD; Dreger P; Krämer A
Blood Cancer J; 2016 Jul; 6(7):e449. PubMed ID: 27471865
[TBL] [Abstract][Full Text] [Related]
7. [Allogeneic stem cell transplantation for 75 cases of acute myeloid leukemia in complete remission: outcome and prognostic analysis].
Song AX; Yang DL; Wei JL; Yan ZS; Wang M; Jiang EL; Huang Y; Liu QG; Ma QL; Zhai WH; Zhang RL; Feng SZ; Han MZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):161-6. PubMed ID: 20137139
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia.
Norkin M; Katragadda L; Zou F; Xiong S; Chang M; Dai Y; Hsu JW; Moreb JS; Leather H; Murthy HS; Farhadfar N; Li Y; Hromas R; Brown RA; Cogle CR; Wingard JR
Blood Cancer J; 2017 Nov; 7(12):634. PubMed ID: 29176662
[TBL] [Abstract][Full Text] [Related]
9. The impact of pre-transplant minimal residual disease on outcome of intensified myeloablative cord blood transplant for acute myeloid leukemia in first or second complete remission.
Zheng C; Zhu X; Tang B; Zhang L; Geng L; Liu H; Sun Z
Leuk Lymphoma; 2016; 57(6):1398-405. PubMed ID: 26690538
[TBL] [Abstract][Full Text] [Related]
10. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic stem cell transplantation for children with acute myeloid leukemia in second remission: A report from the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group.
Selim A; Alvaro F; Cole CH; Fraser CJ; Mechinaud F; O'Brien TA; Shaw PJ; Tapp H; Teague L; Nivison-Smith I; Moore AS
Pediatr Blood Cancer; 2019 Aug; 66(8):e27812. PubMed ID: 31111633
[TBL] [Abstract][Full Text] [Related]
12. The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission.
Zhao XS; Qin YZ; Liu YR; Chang YJ; Xu LP; Zhang XH; Huang XJ
Leuk Lymphoma; 2017 May; 58(5):1135-1143. PubMed ID: 27733089
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic Analysis of Minimal Residual Disease from Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplant by Flow Cytometry].
Hao Q; Zhang SQ; Zhang DM; Wang JB; Zhao J; Cheng HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):239-244. PubMed ID: 29397851
[TBL] [Abstract][Full Text] [Related]
14. Interferon-α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study.
Mo XD; Wang Y; Zhang XH; Xu LP; Yan CH; Chen H; Chen YH; Qin YZ; Liu KY; Huang XJ
Oncologist; 2018 Nov; 23(11):1349-1357. PubMed ID: 30076280
[TBL] [Abstract][Full Text] [Related]
15. CD25 expression on residual leukemic blasts at the time of allogeneic hematopoietic stem cell transplant predicts relapse in patients with acute myeloid leukemia without complete remission.
Ikegawa S; Doki N; Kurosawa S; Yamaguchi T; Sakaguchi M; Harada K; Yamamoto K; Hino Y; Shingai N; Senoo Y; Hattori K; Igarashi A; Najima Y; Kobayashi T; Kakihana K; Sakamaki H; Haraguchi K; Okuyama Y; Ohashi K
Leuk Lymphoma; 2016; 57(6):1375-81. PubMed ID: 26422713
[TBL] [Abstract][Full Text] [Related]
16. Individualized busulfan dosing improves outcomes compared to fixed-dose administration in pre-transplant minimal residual disease-positive acute myeloid leukemia patients with intermediate-risk undergoing allogeneic stem cell transplantation in CR.
Klyuchnikov E; Langebrake C; Badbaran A; Dadkhah A; Massoud R; Freiberger P; Ayuk F; Janson D; Wolschke C; Bacher U; Kröger N
Eur J Haematol; 2023 Feb; 110(2):188-197. PubMed ID: 36335432
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
[TBL] [Abstract][Full Text] [Related]
19. [Effect of minimal residual disease monitoring by multiparameter flow cytometry pre-conditioning on prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Lu Y; Wu T; Wang H; Zhao YL; Cao XY; Liu DY; Zhang JP; Xiong M; Zhou JR; Sun RJ; Wei ZJ; Ji SQ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):118-123. PubMed ID: 28279035
[No Abstract] [Full Text] [Related]
20. [Effect of consolidation before allogeneic hematopoietic stem cell transplantation for non-favorable acute myeloid leukemia patients with first complete remisson and negative minimal residual disease].
Zhang YM; Zhang Y; Ni X; Gao L; Qiu HY; Zhang YS; Tang GS; Chen J; Zhang WP; Wang JM; Yang JM; Hu XX
Zhonghua Xue Ye Xue Za Zhi; 2020 Jan; 41(1):16-22. PubMed ID: 32023749
[No Abstract] [Full Text] [Related]
[Next] [New Search]
